Health Care

VolitionRX insider buys signal management confidence amid a shaky stock, showing a 11% stake shift and potential upside for long‑term investors.

CEO Stanley Bergman sold 38,346 Henry Schein shares just after an earnings beat—insider trade shows routine portfolio balancing, not a red flag.

CEO tax‑sale of 873 Sanara Medtech shares shows minimal impact; investors see it as routine compliance, not a warning sign, amid modest price dip and weak fundamentals.

Envista’s CEO and CFO buy performance‑linked shares, signaling strong confidence in growth while balancing liquidity needs.

Plus Therapeutics CFO Andrew MacIntyre buys 349,542 RSUs & options, signaling confidence amid a $0.28 share price, potential reimbursement boost, and volatile outlook.

Health Catalyst’s CEO buys 930,000 RSUs and 38,833 PRSUs amid a 63 % yearly dip, signaling executive confidence and a strategy to drive future revenue growth.

Immunovant insider sell‑to‑cover by COO Gloria Melanie shows routine tax compliance amid broader executive trading; investors watch for future discretionary sales and potential market impact.

CEO Kent’s $16 share buy at MBX Biosciences shows strong conviction amid 52‑week swings, signaling potential upside for cautious investors.

Thomas Basil’s recent 10b5‑1 sell‑off adds liquidity but remains a planned move, not a confidence warning, as Climb Bio’s growth and fundamentals stay strong.

Caribou Biosciences CTO Kelly Timothy P sells 6,228 shares at $1.93, signaling insider liquidity moves amid rising stock price and mixed executive confidence.